Immunosuppression by Immunoglobulin Deaggregation
Author Information
Author(s): G.B. Sivolapenko, M. Kanariou, R.J. Edwards, A.A. Epenetos, M.A. Ritter
Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
Hypothesis
Can deaggregation of therapeutic monoclonal antibodies reduce their immunogenicity in patients with cancer?
Conclusion
Deaggregation alone is unlikely to control the human anti-murine immunoglobulin G response, but may be more effective when combined with immunosuppressants.
Supporting Evidence
- Deaggregation significantly reduced the immune response in susceptible mice.
- Patients showed no significant difference in immune response to aggregated vs non-aggregated antibodies.
- Combination of deaggregated antibodies with cyclosporin A showed an additive effect in reducing immune response.
Takeaway
The study looked at whether breaking down antibodies could help patients not react to them, but it didn't work well on its own.
Methodology
The study involved both animal experiments and clinical trials with patients receiving different forms of monoclonal antibodies.
Potential Biases
Potential bias due to the small sample size and the specific patient population studied.
Limitations
The study's findings may not be applicable to the general population due to genetic variability in immune responses.
Participant Demographics
Patients with ovarian cancer, receiving monoclonal antibody therapy for the first time.
Statistical Information
P-Value
0.0005
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website